Could carbamazepine-acetazolamide interaction lead to a severe hepatocellular liver injury? an interaction that needs to be uncovered.

Mansour, Khadija; Slim, Raoudha; Sassi, Malek; Ben-Sayed, Nesrine; Fathallah, Neila; Ouni, Bouraoui

Mansour, Khadija; Slim, Raoudha; Sassi, Malek; Ben-Sayed, Nesrine; Fathallah, Neila; Ouni, Bouraoui.

Afiliação

Mansour K; Department of Pharmacology, Fattouma Bourguiba University Hospital, Monastir, Tunisia. khadija.mansour2@gmail.com.
Slim R; Laboratoire de Biophysique Métabolique Et Pharmacologie Appliquée (LR 12ES02), Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisia.
Sassi M; Faculty of Pharmacy of Monastir, Monastir, Tunisia.
Ben-Sayed N; Department of Clinical Hematology, Farhat Hached Hospital, Sousse, Tunisia.
Fathallah N; Laboratoire de Biophysique Métabolique Et Pharmacologie Appliquée (LR 12ES02), Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisia.
Ouni B; Laboratoire de Biophysique Métabolique Et Pharmacologie Appliquée (LR 12ES02), Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisia.

Eur J Clin Pharmacol ; 79(6): 873-874, 2023 06.

Article em En | MEDLINE | ID: mdl-37072528

Assuntos

Carcinoma Hepatocelular; Neoplasias Hepáticas; Humanos; Acetazolamida; Carbamazepina/efeitos adversos; Benzodiazepinas

Palavras-chave

acetazolamide; carbamazepine; drug-drug interaction; liver injury; protein plasma binding

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google